Table 1.
Participant characteristics.
N (female:male) | 223 (142:81) |
---|---|
Age (years) | 66 (53–73) |
BMI (kg/m2) | 23.1 (21.2–26.4) |
Abdominal circumference (cm) | 83.9 (77.0–90.8) |
Subcutaneous fat area (cm2) | 162.7 (108.1–221.8) |
Visceral fat area (cm2) | 86.1 (53.1–119.0) |
HbA1c (%) | 5.8 (5.6–6.2) |
HOMA–R | 1.4 (0.9–2.2) |
T-Chol (mg/dL) | 194.0 (174.0–215.0) |
TG (mg/dL) | 108.0 (77.0–154.5) |
HDL-Chol (mg/dL) | 57.0 (48.5–70.0) |
XOR activity (pmol/h/mL) | 42.7 (25.3–78.6) |
UA (mg/dL) | 5.3 (4.5–6.2) |
UACR | 0.46 (0.40–0.55) |
L/S ratio | 1.3 (1.2–1.5) |
HSI | 32.6 (29.3–37.9) |
AST (U/L) | 20.0 (16.0–25.0) |
ALT (U/L) | 18.0 (13.0–26.0) |
γ-GTP | 21.0 (15.8–32.0) |
Hypertension | 171 (76.7%) |
Diabetes | 51 (22.9%) |
Dyslipidemia | 145 (65.0%) |
The results are presented as median (interquartile range). BMI, body mass index; HbA1c, hemoglobin A1c; HOMA-R, homeostasis model assessment ratio; T-Chol, total-cholesterol; TG, triglycerides; HDL-Chol, high-density lipoprotein-cholesterol; XOR, xanthine oxidoreductase; UA, uric acid; UACR, urine uric acid to creatinine ratio; L/S, liver-to-spleen; HSI, hepatic steatosis index; AST, aspartate transaminase; ALT, alanine transaminase: γ-GTP, γ-glutamyl transpeptidas.